Alumis Inc. (ALMS)
ALMS moved a median of +0.08% 30 minutes after news, and -1.03% by the close. How ALMS actually reacts to news — the realized, point-in-time move the market made, measured across 246 labeled events over the last three years with zero look-ahead.
ALMS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 50% | 242 |
| 30-min | +0.08% | 52% | 244 |
| 60-min | -0.43% | 42% | 244 |
| to close | -1.03% | 47% | 245 |
| Middle 50% of ALMS reactions | -2.47% to +1.44% |
|---|---|
| Median reaction (30-min) | +0.08% |
| Measured reactions | 246 |
Half of all Alumis Inc. news events land between -2.47% and +1.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALMS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.58% | 80% | +1.37% |
| Coverage initiations | 36 | 0.00% | 22% | -4.38% |
| Rating reiterations | 72 | +0.16% | 56% | +1.37% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ALMS ranks against every other measured name →
That’s how ALMS usually reacts — get an email when it moves on news →Email me when ALMS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALMS's baseline. Nothing else.
Recent ALMS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures | Press release | GlobeNewswire | -1.59% | +1.71% | |
| Alumis to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | +0.49% | -1.16% | |
| Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) | Press release | GlobeNewswire | +8.60% | -4.25% | |
| Form 8-K ALUMIS INC. For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +8.60% | -4.25% | |
| Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements | Press release | GlobeNewswire | +1.23% | +9.14% | |
| Form 10-Q ALUMIS INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.23% | +9.14% | |
| Form 8-K ALUMIS INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | +9.14% | |
| Form 8-K ALUMIS INC. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | +3.53% | |
| Form 8-K ALUMIS INC. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -1.06% | +2.80% | |
| Form ARS ALUMIS INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.81% | +1.97% | |
| Form DEF 14A ALUMIS INC. For: Jun 30 | SEC filing · Form DEF | SEC EDGAR | -0.81% | +1.97% | |
| Form DEFA14A ALUMIS INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.81% | +1.97% | |
| Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements | Press release | GlobeNewswire | +1.69% | +1.42% | |
| Form 10-Q ALUMIS INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.69% | +1.42% | |
| Form 8-K ALUMIS INC. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | +1.42% | |
| Form 8-K ALUMIS INC. For: Mar 28 | SEC filing · Form 8-K | SEC EDGAR | -3.75% | -15.79% | |
| Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Press release | GlobeNewswire | -3.75% | -15.79% | |
| Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | Press release | GlobeNewswire | +0.54% | +0.89% | |
| Form 10-K ALUMIS INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.54% | +0.89% | |
| Form 8-K ALUMIS INC. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | +0.89% | |
| Form S-3ASR ALUMIS INC. | SEC filing · Form S-3ASR | SEC EDGAR | +0.54% | +0.89% | |
| Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting | Press release | GlobeNewswire | -1.36% | -3.46% | |
| Alumis to Present at the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | +0.59% | +2.59% | |
| Alumis to Participate in Upcoming February Investor Conferences | Press release | GlobeNewswire | -0.10% | +0.42% | |
| Form S-8 ALUMIS INC. | SEC filing · Form S-8 | SEC EDGAR | +4.46% | +8.01% | |
| Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +3.06% | +7.82% | |
| Form 8-K ALUMIS INC. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | +5.73% | |
| Alumis Announces Pricing of Upsized Public Offering of Common Stock | Press release | GlobeNewswire | +1.86% | -0.38% | |
| Alumis Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -1.83% | +2.75% | |
| Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program | Press release | GlobeNewswire | -10.08% | -26.99% | |
| Form 8-K ALUMIS INC. For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -10.08% | -26.99% | |
| Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis | Press release | GlobeNewswire | -10.08% | -26.99% | |
| Form 8-K ALUMIS INC. For: Jan 02 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -6.63% | |
| Alumis to Participate in Upcoming November Investor Conferences | Press release | GlobeNewswire | +1.80% | +2.48% | |
| Form 8-K ALUMIS INC. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | -1.06% | |
| Alumis to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | -0.84% | -2.32% | |
| Form EFFECT ALUMIS INC. | SEC filing · Form EFFECT | SEC EDGAR | -2.56% | -6.17% | |
| Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.33% | +5.53% | |
| Form 10-Q ALUMIS INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.33% | +5.53% | |
| Form 8-K ALUMIS INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +4.33% | +5.53% | |
| Form 8-K ALUMIS INC. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | +2.19% | |
| Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus | Press release | GlobeNewswire | +1.18% | +0.78% | |
| Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary | Press release | GlobeNewswire | +2.51% | -2.51% | |
| Form S-3 ALUMIS INC. | SEC filing · Form S-3 | SEC EDGAR | — | +0.00% | |
| Form 8-K/A ALUMIS INC. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +1.34% | |
| Form ARS ALUMIS INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.04% | -1.63% | |
| Form DEF 14A ALUMIS INC. For: Jul 30 | SEC filing · Form DEF | SEC EDGAR | +0.04% | -1.63% | |
| Form DEFA14A ALUMIS INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.04% | -1.63% | |
| Form S-8 ALUMIS INC. | SEC filing · Form S-8 | SEC EDGAR | -0.59% | -2.08% | |
| Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis | Press release | GlobeNewswire | -4.75% | -2.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALMS section they belong to.
Where else ALMS is measured.
ALMS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alumis Inc.'s median reaction calculated?
Every labeled ALMS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 246 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ALMS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALMS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.